MARKETSPERPSLIVE110
Cash
Browse
Live110
Portfolio
Search
Social
TrendingElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentions

Finance

Tech & Science
Browse
Live110
Portfolio
Search
Social
Product
Perpetual FuturesMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatory
© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
TrendingElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentions

Finance

Tech & Science

Biotech

All markets
Company Quarterlies
Companies
IPOs
KPIs
Credit Card Spend
Foot Traffic
M&A
CEOs
Indices
Product launches
Industries
Biotech
Compute
Markets
Foreign Exchange
Interest Rates
Match Ups
Biotech

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes
1.42x
No
2.66x
$3,841 vol1 market
Biotech

FDA decision: Brepocitinib by Priovant Therapeutics (this year)

Yes
1.18x
No
4.31x
$2,049 vol1 market
Biotech

FDA decision: Venglustat by Sanofi (this year)

Yes
1.19x
No
4.13x
$446 vol1 market
Biotech

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes
1.34x
No
2.89x
$348 vol1 market
Biotech

FDA decision: Rusfertide by Protagonist Therapeutics (this year)

Yes
1.10x
No
5.90x
$1,605 vol1 market
Biotech

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Yes
1.25x
No
3.29x
$468 vol1 market
Biotech

FDA decision: Iberdomide by BMS/Celgene (this year)

Yes
1.08x
No
6.29x
$5,308 vol1 market
Biotech

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (this year)

Yes
1.34x
No
2.81x
$817 vol1 market
Biotech

FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (this year)

Yes
1.08x
No
6.29x
$658 vol1 market
Biotech

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes
1.31x
No
2.98x
$236 vol1 market
Biotech

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes
1.10x
No
5.90x
$642 vol1 market
Biotech

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes
1.25x
No
3.52x
$488 vol1 market